title: [Chronic lymphocytic leukemia in Subsaharian Africa: clinical outcome experience of Côte d'Ivoire].
abstract: We reported in this retrospective study the clinical outcome of 56 chronic lymphoïd leukemia of black African in Ivory Coast and the predicting prognosis factors. The mean age was 62 years old with average of 38 to 84 years. According to Binet staging, 29 patients with stage A, and respectively 11 and 16 patient for stage B and C. All patient received chemotherapy protocol regimens (CVP, chlorambucil, CHOP). The global response was 51.78%. The death occurred in 29 patients. The mean survival was 8.22 years. The disease free survival was 58.8% at 5 years. In univariate analysis, factors with high-risk of death are patients age above 60 years, the presence of node, liver involvement, Spleen large IV and V of Hackett classification, WBC superior to 100,000/microL, lymphocytosis superior to 63,000/microL, Anaemia inferior to 10 g/dL, thrombopenia inferior to 100,000/microL, medullar lymphocytosis superior to 73% and Binet Stage B and C. In multivariate analysis, only age, adenopathy, hepatomegaly and lymhocytosis were an independent prognostic factor for predicting survival.
authors.affiliation: Service d'hématologie clinique, CHU de Yopougon, 01 BP 3061 Abidjan, Côte d'Ivoire. guskof@yahoo.fr
authors.forename: K G
authors.initials: KG
authors.lastname: Koffi
authors.forename: D C
authors.initials: DC
authors.lastname: Nanho
authors.forename: A
authors.initials: A
authors.lastname: Tolo
authors.forename: E
authors.initials: E
authors.lastname: N'Dathz
authors.forename: B
authors.initials: B
authors.lastname: Kouakou
authors.forename: N
authors.initials: N
authors.lastname: Meite
authors.forename: R
authors.initials: R
authors.lastname: Ayemou
authors.forename: I
authors.initials: I
authors.lastname: Sanogo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002699:Chlorambucil / Q000008:administration & dosage; D007560:Cote d'Ivoire / Q000453:epidemiology; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000401:mortality; D008727:Methotrexate / Q000008:administration & dosage; D008775:Methylprednisolone / Q000008:administration & dosage; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D012189:Retrospective Studies; D017678:Sex Distribution; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D002699:Chlorambucil; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone; D006854:Hydrocortisone; D008775:Methylprednisolone; D008727:Methotrexate